6
Mar 2026
Redefining end-of-life care for better patient outcomes
Specialist palliative care has the potential to reduce costs by up to £8,000 per person and improve quality of life.

Increasing and changing demands concerning the health of populations and limited resources require our health care organizations and systems to rethink their sustainability. To achieve objectives, such as improved healthcare quality, health outcomes, efficiency and staff satisfaction, we support our clients in making evidence-based decisions. With tailor-made research projects, we provide insights into what works, for whom, at what cost, and under what circumstances. Based on your challenge, we can support you by:
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
6
Mar 2026
Specialist palliative care has the potential to reduce costs by up to £8,000 per person and improve quality of life.
6
Mar 2026
A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without causing systemic side effects. A research team from Pohang University of Science and Technology (POSTECH) and Ewha Womans University has developed the "Immune-Shield" technology, which directly sprays immunosuppressants onto the surface of organs using mussel-derived adhesive protein.
6
Mar 2026
Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.
6
Mar 2026
Antimicrobial resistance (AMR) threatens human, animal, and environmental health globally. An international team from leading institutions, including the University of Edinburgh, London School of Hygiene and Tropical Medicine, North Carolina State University, and the International Centre for Antimicrobial Resistance Solutions, identifies fundamental gaps in current mathematical modelling approaches that prevent translation of science into policy, including data limitations, knowledge gaps about AMU-AMR relationships, and the absence of international coordination mechanisms similar to climate change efforts. They call for transdisciplinary collaboration to build integrated modelling architectures.